NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
71921-0177-06 | 71921-0177 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | April 10, 2023 | In Use | |
72162-1878-06 | 72162-1878 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 30, 2023 | In Use | |
72162-1879-06 | 72162-1879 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 30, 2023 | In Use | |
72162-1880-06 | 72162-1880 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 30, 2023 | In Use | |
72189-0415-30 | 72189-0415 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 30, 2023 | In Use | ||
72189-0430-10 | 72189-0430 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 3, 2023 | In Use | |
72189-0430-20 | 72189-0430 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 3, 2023 | In Use | |
72189-0430-21 | 72189-0430 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 3, 2023 | In Use | |
72189-0468-15 | 72189-0468 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 4, 2023 | In Use | |
72189-0468-21 | 72189-0468 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 4, 2023 | In Use | |
72606-0011-01 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0011-10 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0012-01 | 72606-0012 | Bevacizumab-adcd | Vegzelma | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72606-0012-10 | 72606-0012 | Bevacizumab-adcd | Vegzelma | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | April 3, 2023 | In Use | |
72819-0152-95 | 72819-0152 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | March 11, 2022 | In Use | |
72819-0152-05 | 72819-0152 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
72819-0153-02 | 72819-0153 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
72819-0154-04 | 72819-0154 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
72974-0120-01 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Dec. 18, 2020 | In Use | |
72974-0120-97 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Oct. 21, 2021 | In Use | |
72974-0120-95 | 72974-0120 | Relugolix | Orgovyx | 120.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Oral | Jan. 27, 2023 | In Use | |
80425-0075-01 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-02 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-03 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-04 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use |
Found 10,000 results in 8 milliseconds — Export these results